Logo

AstraZeneca's Tagrisso (osimertinib) Receives EU's CHMP Positive Opinion for the Adjuvant Treatment of Patients with Early-Stage EGFR-Mutated Lung Cancer

Share this

AstraZeneca's Tagrisso (osimertinib) Receives EU's CHMP Positive Opinion for the Adjuvant Treatment of Patients with Early-Stage EGFR-Mutated Lung Cancer

Shots:

  • The recommendation is based P-III ADAURA trial assessing Tagrisso (80mg- qd- PO) vs PBO in 682 patients with stage IB- II- IIIA EGFRm NSCLC following complete tumor resection and adjuvant CT as indicated for 3 yrs. or until disease recurrence
  • The study showed improvement in DFS in all primary analysis population of patients with Stage II and IIIA EGFRm NSCLC and in the overall trial population of patients with Stage IB-IIIA disease- 80% reduction in the risk of disease recurrence or death
  • Tagrisso is approved to treat early-stage lung cancer in more than 15 countries- including US and China- and additional global regulatory reviews are ongoing

  Ref: AstraZeneca | Image: Al Jazeera

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions